Latest

30
Nov
Bridges to nowhere

Bridges to nowhere

Is China in danger of financial collapse? Victor Shih on the huge structural risks underlying the economy of the People’s Republic.
14 min read
26
Nov
Unspeakable

Unspeakable

How are the repercussions of protest and violence in Charlottesville, Virginia, shaping the limits of free expression in the U.S.? Nadine Strossen on the legal aftermath of a shocking event.
13 min read
23
Nov
Friends like these

Friends like these

Why is democracy eroding more among America’s allies than in other countries? Moises Naím on how massive social change is affecting the way citizens feel, and the nature of politics, around the world.
10 min read
18
Nov
War games

War games

Why is Moscow massing troops at the Ukrainian border? Anatol Lieven on what Vladimir Putin is after.
10 min read
16
Nov
Divided attention

Divided attention

In the U.S., is the Democratic Party losing ground on culture-war issues? David Kusnet on the party’s recurring struggle to “speak American.”
15 min read
12
Nov
Into the fog

Into the fog

What’s separation from Europe meant for life in the U.K. through an uncertain pandemic? Matthias Matthijs on how Brexit is transforming politics and the economy in Britain and Northern Ireland.
15 min read
11
Nov
Course corrections

Course corrections

Is U.S. higher education really broken? Jonathan Zimmerman on the contemporary American college and its critics.
15 min read
09
Nov
Generals and rebels

Generals and rebels

Why is it so hard to build a democracy? James A. Robinson on the coup in Sudan and the challenge of making inclusive institutions from the debris of tyranny.
14 min read
05
Nov
‘The golden age of spaceflight’

‘The golden age of spaceflight’

What’s driving all the new activity in the commercial-spaceflight industry? Joe Pappalardo on Jeff Bezos, Elon Musk, and how a capital-intensive business has started to shape the future.
17 min read
04
Nov
Trade secrets

Trade secrets

Why aren’t Covid-19 vaccine makers allowing other manufacturers to produce more doses? James Love on the hype and reality of the new drug technology, messenger RNA.
14 min read